Formulation and immunological evaluation of novel vaccine delivery systems based on bioresorbable poly(ethylene glycol)-block-poly(lactide-co-ε-caprolactone)
Ming-Hsi Huang
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorAi-Hsiang Chou
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorShu-Pei Lien
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorHsin-Wei Chen
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorChiung-Yi Huang
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorWei-Wen Chen
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorPele Chong
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorCorresponding Author
Shih-Jen Liu
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, TaiwanSearch for more papers by this authorCorresponding Author
Chih-Hsiang Leng
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, TaiwanSearch for more papers by this authorMing-Hsi Huang
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorAi-Hsiang Chou
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorShu-Pei Lien
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorHsin-Wei Chen
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorChiung-Yi Huang
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorWei-Wen Chen
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorPele Chong
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Search for more papers by this authorCorresponding Author
Shih-Jen Liu
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, TaiwanSearch for more papers by this authorCorresponding Author
Chih-Hsiang Leng
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, Taiwan
Vaccine Research and Development Center, National Health Research Institutes, Zhunan, Miaoli 35053, TaiwanSearch for more papers by this authorAbstract
Novel emulsion-type vaccine delivery systems based on the amphiphilic bioresorbable polymer poly(ethylene glycol)-block-poly(lactide-co-ε-caprolactone) (PEG-b-PLACL) and selected oils were developed here. Physicochemical characterizations such as stability, a droplet test, microscopic aspects, and in vitro release showed that PEG-b-PLACL-emulsified formulations have several advantages over traditional vaccine adjuvants in that they are stable, reproducible, and homogeneous fine particles with an appropriate size to facilitate the induction of potent immune responses. Different dispersion-type emulsions have provided different release profiles using ovalbumin in model studies. Immunogenicity studies in mice have shown that antigen-specific antibody titers and T-cell proliferative responses, as well as the secretion of IFN-γ, were significantly enhanced for ovalbumin after formulation with PEG-b-PLACL-based emulsions. These features are of great interest for applications in delivery systems of prophylactic and therapeutic vaccine candidates. © 2009 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater 2009
REFERENCES
- 1 Guy B. The perfect mix: Recent progress in adjuvant research. Nat Rev Microbiol 2007; 5: 505–517.
- 2 McKee AS,Munks MW,Marrack P. How do adjuvants work? Important considerations for new generation adjuvants. Immunity 2007; 27: 687–690.
- 3 Pashine A,Valiante NM,Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med 2005; 11: S63–S68.
- 4 Singh M,O'Hagan DT. Advances in vaccine adjuvants. Nat Biotech 1999; 17: 1075–1081.
- 5 Gupta RK. Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev 1998; 32: 155–172.
- 6 Aucouturier J,Dupuis L,Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 2001; 19: 2666–2672.
- 7 Brancq B,Trouve G. Injectable multi-phase emulsions. U.S. Pat. No. 5,424,067 ( 1995).
- 8 Dupuis M,Murphy TJ,Higgins D,Ugozzoli M,van Nest G,Ott G,McDonald DM. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol 1998; 186: 18–27.
- 9 Allison AC. Squalene and squalane emulsions as adjuvants. Methods 1999; 19: 87–93.
- 10 Miles AP,McClellan HA,Rausch KM,Zhu D,Whitmore MD,Singh S,Martin LB,Wu Y,Giersing BK,Stowers AW,Long CA,Saul A. Montanide® ISA 720 vaccines: Quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine 2005; 23: 2530–2539.
- 11 Ott G,Barchfeld GL,Van Nest G. Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59. Vaccine 1995; 13: 1557–1562.
- 12 van Zuylen L,Verweij J,Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs 2001; 19: 125–141.
- 13 Gaucher G,Poreba M,Ravenelle F,Leroux JC. Poly(N-vinyl-pyrrolidone)-block-poly(D,L-lactide) as polymeric emulsifier for the preparation of biodegradable nanoparticles. J Pharm Sci 2007; 96: 1763–1775.
- 14 Jeong B,Bae YH,Lee DS,Kim SW. Biodegradable block copolymers as injectable drug-delivery systems. Nature 1997; 388: 860–862.
- 15 Youan BBC,Jackson TL,Dickens L,Hernandez C,Owusu-Ababioa G. Protein release profiles and morphology of biodegradable microcapsules containing an oily core. J Control Release 2001; 76: 313–326.
- 16 Huang MH,Li S,Hutmacher DW,Coudane J,Vert M. Degradation characteristics of poly(ε-caprolactone)-based copolymers and blends. J Appl Polym Sci 2006; 102: 1681–1687.
- 17 Shim WS,Kim JH,Park H,Kim K,Kwon IC,Lee DS. Biodegradability and biocompatibility of a pH- and thermo-sensitive hydrogel formed from a sulfonamide-modified poly(ε-caprolactone-co-lactide)-poly(ethylene glycol)-poly(ε-caprolactone-co-lactide) block copolymer. Biomaterials 2006; 27: 5178–5185.
- 18 Zhang Y,Wang C,Yang W,Shi B,Fu S. Tri-component diblock copolymers of poly(ethylene glycol)-poly(ε-caprolactone-co-lactide): Synthesis, characterization and loading camptothecin. Colloid Polym Sci 2005; 283: 1246–1252.
- 19 Umbreit JN,Strominger JL. Relation of detergent HLB number to solubilization and stabilization of D-alanine carboxypeptidase from Bacillus subtilis membranes. Proc Natl Acad Sci USA 1973; 70: 2997–3001.
- 20 Reddy ST,Swartz MA,Hubbell JA. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol 2006; 27: 573–579.
- 21 Wang C,Ge Q,Ting D,Nguyen D,Shen HR,Chen J,Eisen HN,Heller J,Langer R,Putnam D. Molecularly engineered poly(ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004; 3: 190–196.
- 22 Yang YW,Wei AC,Shen SS. The immunogenicity-enhancing effect of emulsion vaccine adjuvants is independent of the dispersion type and antigen release rate-a revisit of the role of the hydrophile-lipophile balance (HLB) value. Vaccine 2005; 23: 2665–2675.
- 23 Zhu G,Mallery SR,Schwendeman SP. Stabilization of proteins encapsulated in injectable poly (lactide-co-glycolide). Nat Biotechnol 2000; 18: 52–57.
- 24 Grayson ACR,Choi IS,Tyler BM,Wang PP,Brem H,Cima MJ,Langer R. Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2003; 2: 767–772.
- 25 Napoli A,Valentini M,Tirelli N,Müller M,Hubbell JA. Oxidation-responsive polymeric vesicles. Nat Mater 2004; 3: 183–189.
- 26 Newman MJ,Balusubramanian M,Todd CW. Development of adjuvant-active nonionic block copolymers. Adv Drug Deliv Rev 1998; 32: 199–223.
- 27 Todd CW,Pozzi LA,Guarnaccia JR,Balasubramanian M,Henk WG,Younger LE,Newman MJ. Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations. Vaccine 1997; 15: 564–570.
